Acorda Positions Ampyra For Large Market Of Post-Stroke Deficits
This article was originally published in The Pink Sheet Daily
Acorda plans to move Ampyra to Phase III for treating post-stroke deficits, after reporting positive Phase II results. The company also reported a signal from a small proof-of-concept study in cerebral palsy, but next steps are unclear in that indication.
You may also be interested in...
Mylan sticks with Abbott deal, confident that it will be a successful tax inversion, while AbbVie rules out similar deals after walking away from Shire upon deciding recent tax policy changes rule out its own inversion play. Other updates from the third-quarter earnings calls, in brief.
Novo Nordisk and Allergan both report setbacks during their respective first quarter earnings calls. Meanwhile, Valeant and Actavis avoid speculation about a potential merger, and other Q1 happenings.
Acorda Therapeutics' challenges in seeking approval for its oral therapy Ampyra to improve walking ability in patients with multiple sclerosis were greater than most from the start: it was a novel drug for a first-of-its-kind claim – and the drug yielded variable efficacy on an unproven endpoint. What seems to have made the difference is the creative analysis plan that Acorda came up with.